MTX-101 / Manistee Therapeutics - LARVOL DELTA

Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults (clinicaltrials.gov) - P2 | N=78 | Completed | Sponsor: Manistee Therapeutics | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Migraine • Pain

Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults (clinicaltrials.gov) - P2 | N=72 | Active, not recruiting | Sponsor: Manistee Therapeutics | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Migraine • Pain

Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults (clinicaltrials.gov) - P2 | N=72 | Recruiting | Sponsor: Manistee Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Migraine • Pain